Valeritas (NASDAQ:VLRX) Upgraded by Zacks Investment Research to “Hold”

Valeritas (NASDAQ:VLRX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Wednesday, Zacks.com reports.

According to Zacks, “Valeritas Holdings Inc. is a commercial-stage medical technology company which focused on developing technologies for Type 2 diabetes. The company’s product pipeline consists of V-Go (R) Disposable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery solution for Type 2 diabetes which enables patients to administer a continuous preset basal rate infusion of insulin. Valeritas Holdings Inc. is headquartered in Bridgewater, New Jersey. “

Other equities analysts have also recently issued reports about the company. BTIG Research cut Valeritas from a “buy” rating to a “neutral” rating in a research note on Monday, December 23rd. ValuEngine cut Valeritas from a “buy” rating to a “hold” rating in a research note on Saturday, December 21st. Finally, Oppenheimer cut Valeritas from an “outperform” rating to a “market perform” rating in a research note on Monday, December 23rd.

VLRX traded down $0.02 during trading hours on Wednesday, hitting $0.75. 7,800 shares of the stock were exchanged, compared to its average volume of 427,830. The stock has a 50-day simple moving average of $1.08 and a 200-day simple moving average of $1.75. Valeritas has a 12 month low of $0.55 and a 12 month high of $11.39. The stock has a market cap of $6.41 million, a price-to-earnings ratio of -0.02 and a beta of 1.78. The company has a debt-to-equity ratio of 1.74, a current ratio of 2.08 and a quick ratio of 1.63.

Valeritas (NASDAQ:VLRX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.91) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.52) by $0.61. Valeritas had a negative return on equity of 1,142.30% and a negative net margin of 183.82%. The firm had revenue of $8.46 million for the quarter. Sell-side analysts expect that Valeritas will post -9.49 EPS for the current year.

In related news, major shareholder Armistice Capital, Llc sold 1,060,000 shares of the firm’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $0.75, for a total transaction of $795,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 1.02% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp acquired a new stake in Valeritas in the second quarter worth $68,000. Millennium Management LLC acquired a new stake in Valeritas in the third quarter worth $77,000. Finally, Wedbush Securities Inc. increased its position in Valeritas by 449.1% in the fourth quarter. Wedbush Securities Inc. now owns 90,000 shares of the company’s stock worth $52,000 after buying an additional 73,609 shares during the period. Hedge funds and other institutional investors own 17.30% of the company’s stock.

Valeritas Company Profile

Valeritas Holdings, Inc, a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization.

Recommended Story: Holder of Record

Get a free copy of the Zacks research report on Valeritas (VLRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with MarketBeat.com's FREE daily email newsletter.